{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:09:07Z","timestamp":1740143347400,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Norbrook Laboratories Limited","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100007765","name":"Kansas State University","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007765","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Veterinary and Biomedical Research Center Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Osteoarthritis (OA) affects nearly 20% of all dogs greater than one year of age. Clinical signs include pain, discomfort, lameness, and ultimately lead to disability. Although there is currently no known cure, there are many therapeutic options that can slow the progression and alleviate the associated signs. There is ample supportive evidence demonstrating the efficaciousness of carprofen, a non-steroidal anti-inflammatory drug, in managing signs of OA. Since the approval of the pioneer product (Rimadyl\u00ae, Zoetis; Kalamazoo, Michigan), the United States Food and Drug Administration (FDA) has assented to several other generic, bioequivalent products. The objective of this 2\u2009\u00d7\u20092 complete cross-over design was to assess the acceptance of two bioequivalent carprofen liver-flavored chewable tablets (containing 25\u2009mg carprofen), Rimadyl\u00ae and Carprieve\u00ae (Norbrook Laboratories Limited; Newry, Northern Ireland) in 37 healthy purpose-bred dogs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 73.0% (27\/37) and 70.3% (26\/37) of dogs voluntarily accepted Rimadyl\u00ae and Carprieve\u00ae, respectively. Considering acceptability tests paired by individual dog, 64.9% of dogs (<jats:italic>n<\/jats:italic>\u2009=\u200924) voluntarily accepted both Rimadyl\u00ae and Carprieve\u00ae chewable tablets whereas 21.6% (8) of dogs denied or partially accepted both products offered. Three dogs (8.1%) fully accepted Rimadyl\u00ae but did not accept Carprieve\u00ae. Conversely, two dogs (5.4%) fully accepted Carprieve\u00ae but did not accept Rimadyl\u00ae. Canine acceptability did not significantly differ between Carprieve\u00ae and Rimadyl\u00ae carprofen chewable tablets (<jats:italic>P<\/jats:italic>\u2009=\u20090.65).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Utilizing a 2\u2009\u00d7\u20092 complete cross-over design, this study provides evidence that canine acceptability of a single-dose did not differ between Carprieve\u00ae and Rimadyl\u00ae chewable tablets.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12917-019-2124-1","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T17:03:46Z","timestamp":1572973426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A complete cross-over design evaluating canine acceptance of Carprieve\u00ae and Rimadyl\u00ae carprofen chewable tablets in healthy dogs"],"prefix":"10.1186","volume":"15","author":[{"given":"Diana M. A.","family":"Dewsbury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"DeDonder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell J.","family":"Rezac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-6470","authenticated-orcid":false,"given":"Natalia","family":"Cernicchiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,5]]},"reference":[{"issue":"4","key":"2124_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0195-5616(97)50076-3","volume":"27","author":"SA Johnston","year":"1997","unstructured":"Johnston SA. Osteoarthritis, joint anatomy, physiology and pathobiology. Vet Clin North Am Small Anim Pract. 1997;27(4):699\u2013723.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2124_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/vr.164.14.418","volume":"164","author":"RO Sanderson","year":"2009","unstructured":"Sanderson RO, Beata C, Flipo RM, Genevois JP, Macias C, Tacke S, Vezzoni A, Innes JF. Systematic review of the management of canine osteoarthritis. Vet Rec. 2009;164:418\u201324.","journal-title":"Vet Rec."},{"issue":"4","key":"2124_CR3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0195-5616(97)50087-8","volume":"27","author":"JL Cook","year":"1997","unstructured":"Cook JL, Payne JT. Surgical treatment of osteoarthritis. Vet Clin North Am Small Anim Pract. 1997;27(4):931\u201344.","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"3","key":"2124_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2460\/ajvr.68.3.251","volume":"68","author":"BM Brainard","year":"2007","unstructured":"Brainard BM, Meredith CP, Callan MB, Budsberg SC, Shofer FS, Driessen B, Otto CM. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. Am J Vet Res. 2007;68(3):251\u20137.","journal-title":"Am J Vet Res"},{"key":"2124_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/vr.150.22.684","volume":"150","author":"VJ Lipscomb","year":"2002","unstructured":"Lipscomb VJ, AliAbadi FS, Lees P, Pead MJ, Muir P. Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis. Vet Rec. 2002;150:684\u20139.","journal-title":"Vet Rec"},{"key":"2124_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1136\/vr.160.13.427","volume":"160","author":"S Mansa","year":"2007","unstructured":"Mansa S, Palm\u00e9r E, Gr\u00f8ndahl C, L\u00f8naas L, Nyman G. Long-term treatment with carprofen of 805 dogs with osteoarthritis. Vet Rec. 2007;160:427\u201330.","journal-title":"Vet Rec."},{"key":"2124_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/vr.152.11.323","volume":"152","author":"M Moreau","year":"2003","unstructured":"Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. 2003;152:323\u20139.","journal-title":"Vet Rec."},{"key":"2124_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/vr.159.17.547","volume":"159","author":"M Pollmeier","year":"2006","unstructured":"Pollmeier M, Toulemonde C, Fleishman C, Hanson PD. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Vet Rec. 2006;159:547\u201351.","journal-title":"Vet Rec."},{"issue":"6","key":"2124_CR9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2460\/javma.1995.206.06.807","volume":"206","author":"PB Vasseur","year":"1995","unstructured":"Vasseur PB, Johnson AL, Budsberg SC, Lincoln JD, Toombs JP, Whitehair JG, Lentz EL. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc. 1995;206(6):807\u201311.","journal-title":"J Am Vet Med Assoc"},{"unstructured":"United States Food and Drug Administration: Get the facts about pain relievers for pets. https:\/\/www.fda.gov\/AnimalVeterinary\/ResourcesforYou\/AnimalHealthLiteracy\/ucm392732.htm#Approved (2018). [Accessed 17 Jan 2018].","key":"2124_CR10"},{"key":"2124_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/618216","volume":"2015","author":"Zita Talamonti","year":"2015","unstructured":"Talamonti Z, Cassis C, Brambilla PG, Scarpa P, Stefanello D, Cannas S, Minero M, Palestrini C. Preliminary study of pet owner adherence in behavior, cardiology, urology, and oncology fields. Vet Med Int. 2015. https:\/\/doi.org\/10.1155\/2015\/618216 .","journal-title":"Veterinary Medicine International"},{"key":"2124_CR12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.addr.2004.02.012","volume":"56","author":"AG Thombre","year":"2004","unstructured":"Thombre AG. Oral delivery of medications to companion animals: palatability considerations. Adv Drug Del Rev. 2004;56:1399\u2013413.","journal-title":"Adv Drug Del Rev"},{"unstructured":"DVM360.com : New study confirms pet owners\u2019 concerns about veterinary care costs. http:\/\/veterinarynews.dvm360.com\/print\/402954?page=full [Accessed 07 Dec 2018].","key":"2124_CR13"},{"unstructured":"National Research Council: Guide for the care and use of laboratory animals, Eighth Edition. Available from: https:\/\/grants.nih.gov\/grants\/olaw\/guide-for-the-care-and-use-of-laboratory-animals.pdf (2011) [Accessed 25 Jan 2019].","key":"2124_CR14"},{"unstructured":"Sealed Envelope Ltd: Power calculator for binary outcome equivalence trial. Available from: https:\/\/www.sealedenvelope.com\/power\/binary-equivalence\/ (2012) [Accessed 21 Jan 2019].","key":"2124_CR15"},{"key":"2124_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/ani5010043","volume":"5","author":"GC Aldrich","year":"2015","unstructured":"Aldrich GC, Koppel K. Pet food palatability evaluation: a review of standard assay techniques and interpretation of results with a primary focus on limitations. Animals. 2015;5:43\u201355.","journal-title":"Animals."},{"key":"2124_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4236\/ojvm.2018.88011","volume":"8","author":"M Aleo","year":"2018","unstructured":"Aleo M, Ross S, Becskei C, Coscarelli E, King V, Darling M, Lorenz J. Palatability testing of oral chewables in veterinary medicine for dogs. Open J Vet Med. 2018;8:107\u201318.","journal-title":"Open J Vet Med"},{"issue":"8\u20139","key":"2124_CR18","first-page":"431","volume":"157","author":"M Payne-Johnson","year":"2006","unstructured":"Payne-Johnson M, Maitland TP, Bullard J, Gossellin J. Comparative palatability of three commercial formulations of carprofen and one commercial formulation of firocoxib in dogs. Revue M\u00e9d V\u00e9t. 2006;157(8\u20139):431\u201340.","journal-title":"Revue M\u00e9d V\u00e9t."},{"issue":"10","key":"2124_CR19","first-page":"519","volume":"158","author":"M Payne-Johnson","year":"2007","unstructured":"Payne-Johnson M, Maitland TP, Tilt N, Gossellin J. An evaluation of the relative palatability of two commercial oral tablet formulations of carprofen and meloxicam in dogs using acceptance and preference tests. Revue M\u00e9d V\u00e9t. 2007;158(10):519\u201324.","journal-title":"Revue M\u00e9d V\u00e9t"},{"issue":"2","key":"2124_CR20","first-page":"67","volume":"161","author":"J Gossellin","year":"2010","unstructured":"Gossellin J, Maitland TP, Civil J. Relative preference of dogs for two commercial oral tablet formulations of carprofen. Revue M\u00e9d V\u00e9t. 2010;161(2):67\u201371.","journal-title":"Revue M\u00e9d V\u00e9t"},{"unstructured":"Valley Vet Supply: Carprofen chewable tablets. https:\/\/www.valleyvet.com\/search.html?gas=carprofen%20chewable%20tablets [Accessed 16 Jan 2019].","key":"2124_CR21"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-019-2124-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-2124-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T08:52:49Z","timestamp":1721983969000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-019-2124-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1186\/s12917-019-2124-1","relation":{},"ISSN":["1746-6148"],"issn-type":[{"type":"electronic","value":"1746-6148"}],"subject":[],"published":{"date-parts":[[2019,11,5]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No human subjects, human material or human data were involved in this research.This study was conducted as a non-good laboratory practice (non-GLP) study at the Veterinary and Biomedical Research Center, Inc. (VBRC, Inc.; Manhattan, KS), a GLP compliant and fully accredited Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) facility. The study protocol was internally reviewed and approved by the Norbrook Laboratories Limited Research and Development personnel. Additionally, the study protocol was submitted to the VBRC, Inc. Institution for Animal Care and Use Committee (IACUC) where the protocol received approval prior to study initiation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors KD and DR are employed by VBRC, Inc., the contract research organization where the study was conducted. NC is employed by Kansas State University. DD is co-employed by Kansas State University and VBRC, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"394"}}